Insert-tag-herehttps://www.nytimes.com/2021/10/12/health/coronavirus-mutation-variants.html?referringSource=articleShare This article in today's NY Times describes the theoretical evolution of the COVID-19 virus. Inferentially, it makes the case for the long term need for effective therapies for treatment of severe and critical afflicted patients. Near the end of the article note is made of the mechanics of the virus binding to individual cells. IMO If, as we believe, Leronlimab prevents that binding, acting as a shield, CYTODYN is spot on for pursuing the COVID-19 trials. The world's population will need such a therapy if in fact COVID-19 is here to stay in its various mutations.